| ORIGINAL ARTICLE |
|
| Year : 2018 | Volume
: 14
| Issue : 10 | Page : 730-735 |
|
|
Evaluation of the use of nab-paclitaxel and gemcitabine in clinical practice
Cristina Casanova-Martinez, Elena Yaiza Romero-Ventosa, Sonia González-Costas, Cecilia Arroyo-Conde, Guadalupe Piñeiro-Corrales
Hospital Pharmacy Service, Estructura Organizativa de Gestión Integrada de Vigo – Hospital, Álvaro Cunqueiro, Vigo, Pontevedra, Spain
Correspondence Address:
Cristina Casanova-Martinez
Casanova-Martínez, Camiño dos Cañotais 44, 36212 Vigo, Pontevedra
Spain
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0973-1482.188292
|
|
|
Context: Pancreatic cancer in a common tumor in our country for which there are various treatment alternatives.
Objective: Evaluate the effectiveness and safety of nab-paclitaxel and gemcitabine in everyday clinical practice.
Settings and Design: Observational, retrospective study at a tertiary university hospital.
Subjects and Methods: We included patients diagnosed of metastatic or locally advanced pancreatic cancer that were being treated with nab-paclitaxel and gemcitabine. We recorded response, progression-free survival (PFS), and overall survival (OS) rates together with toxicities.
Statistical Analysis Used: We used SPSS program for Windows. We conducted descriptive statistics using averages, medians, standard deviations or ranges, and percentages.
Results: We included 15 patients. At 3 months, there were no complete responses; 20% showed partial responses, and in 60% of patients, the disease stabilized. The median PFS was 8.9 months and the OS was 9.6. The most important adverse reactions were neutropenia, fatigue, and nausea/vomiting.
Conclusions: The treatment regimen leads to increased survival in these patients with an acceptable toxicity profile.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
